title: 3,5,4'-Tri-O-acetylresveratrol decreases seawater inhalation-induced acute lung injury by interfering with the NF-κB and i-NOS pathways.
abstract: Drowning is a cause of accidental mortality. However, survival may result in acute lung injury. The aim of the present study was to evaluate the effects of 3,5,4'-tri-O-acetylresveratrol (AC-Res) on acute lung injury (ALI) induced by seawater inhalation in rats. ALI models were established by the tracheal instillation of artificial seawater with or without 50 mg/kg AC-Res pretreatment for 7 days. Lung samples from different groups were harvested 4 h after the model was established. Histological changes, blood vessel permeability, inflammatory factor secretion and expression states of the nuclear factor-κB (NF-κB) and inducible NOS (i-NOS) pathway were assessed to evaluate seawater‑induced lung injury and the protective effects of acetylated resveratrol. The results showed that seawater inspiration led to physiological structure changes and an increased permeability of blood vessels. In addition, seawater stimulation enhanced the expression levels of nitric oxide (NO), tumor necrosis factor α (TNF-α) and interleukin-1 β (IL-1β) secretion in vitro and in vivo. Notably, seawater inhalation increased NF-κB and i-NOS expression in lungs and cells. On the other hand, pretreatment of AC-Res inhibited the abnormal expression of the NF-κB and i-NOS pathways, followed by decreased NO, TNF-α and IL-1β secretion, protein and cell content in bronchoalveolar lavage fluid (BALF) and Evans blue, protein and cell infiltration from blood vessels into lung tissues. The results therefore suggest that AC-Res attenuated seawater inhalation induced‑ALI by interfering with the NF-κB and i-NOS pathways.
authors.affiliation: Department of Respiration, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China.
authors.forename: Lijie
authors.initials: L
authors.lastname: Ma
authors.affiliation: Department of Respiration, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China.
authors.forename: Xiangjun
authors.initials: X
authors.lastname: Chen
authors.affiliation: Department of Respiration, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China.
authors.forename: Ruixuan
authors.initials: R
authors.lastname: Wang
authors.affiliation: Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China.
authors.forename: Hongtao
authors.initials: H
authors.lastname: Duan
authors.affiliation: Department of Medicinal Chemistry, School of Pharmacy, The Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China.
authors.forename: Libin
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Medicinal Chemistry, School of Pharmacy, The Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China.
authors.forename: Li
authors.initials: L
authors.lastname: Liang
authors.affiliation: Department of Respiration, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China.
authors.forename: Yandong
authors.initials: Y
authors.lastname: Nan
authors.affiliation: Department of Medicinal Chemistry, School of Pharmacy, The Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China.
authors.forename: Xueying
authors.initials: X
authors.lastname: Liu
authors.affiliation: Department of Respiration, Kunming General Hospital of Chengdu Military Command, Kunming, Yunnan 650032, P.R. China.
authors.forename: Ao
authors.initials: A
authors.lastname: Liu
authors.affiliation: Department of Respiration, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China.
authors.forename: Faguang
authors.initials: F
authors.lastname: Jin
mesh_terms: D000107:Acetylation; D055371:Acute Lung Injury / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology / Q000473:pathology; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000737:chemistry / Q000627:therapeutic use*; D053583:Interleukin-1beta / Q000276:immunology; D008168:Lung / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D008297:Male; D016328:NF-kappa B / Q000276:immunology*; D052247:Nitric Oxide Synthase Type II / Q000276:immunology*; D017207:Rats, Sprague-Dawley; D000077185:Resveratrol; D012623:Seawater / Q000009:adverse effects; D015398:Signal Transduction / Q000187:drug effects; D013267:Stilbenes / Q000737:chemistry / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D053583:Interleukin-1beta; D016328:NF-kappa B; D013267:Stilbenes; D052247:Nitric Oxide Synthase Type II; D000077185:Resveratrol